Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APTX
CUSIPN/A
Phone847-871-0377
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees64
Outstanding Shares33,500,000
Market Cap$714.16 million
Aptinyx (NASDAQ:APTX) Frequently Asked Questions
What is Aptinyx's stock symbol?
Aptinyx trades on the NASDAQ under the ticker symbol "APTX."
How were Aptinyx's earnings last quarter?
Aptinyx Inc (NASDAQ:APTX) released its earnings results on Tuesday, August, 14th. The company reported ($1.83) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $1.35. The business had revenue of $2.13 million for the quarter, compared to the consensus estimate of $2.10 million. View Aptinyx's Earnings History.
When is Aptinyx's next earnings date?
What price target have analysts set for APTX?
4 Wall Street analysts have issued 1-year target prices for Aptinyx's stock. Their forecasts range from $30.00 to $35.00. On average, they anticipate Aptinyx's share price to reach $32.3333 in the next year. This suggests a possible upside of 41.8% from the stock's current price. View Analyst Price Targets for Aptinyx.
What is the consensus analysts' recommendation for Aptinyx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.
Who are some of Aptinyx's key competitors?
Some companies that are related to Aptinyx include The Medicines (MDCO), Ascendis Pharma A/S (ASND), Emergent Biosolutions (EBS), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), Global Blood Therapeutics (GBT), Myokardia (MYOK), Akorn (AKRX), Spectrum Pharmaceuticals (SPPI), Xencor (XNCR), Cambrex (CBM), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Phibro Animal Health (PAHC) and Prestige Brands (PBH).
Who are Aptinyx's key executives?
Aptinyx's management team includes the folowing people:
- Mr. Norbert G. Riedel, Pres, CEO & Director (Age 60)
- Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 67)
- Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
- Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 42)
- Mr. Nicholas C. Smith, Director of Corp. Devel.
When did Aptinyx IPO?
(APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
When did the company's quiet period expire?
Aptinyx's quiet period expired on Tuesday, July 31st. Aptinyx had issued 6,399,999 shares in its public offering on June 21st. The total size of the offering was $102,399,984 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
Has Aptinyx been receiving favorable news coverage?
News articles about APTX stock have trended positive on Saturday, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aptinyx earned a news and rumor sentiment score of 0.27 on Accern's scale. They also gave media stories about the company an impact score of 48.26 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Aptinyx.
Who are Aptinyx's major shareholders?
Aptinyx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Frazier Management LLC (9.80%), Partner Fund Management L.P. (4.24%), NF Trinity Capital Hong Kong Ltd (2.18%), Victory Capital Management Inc. (2.16%), Laurion Capital Management LP (0.77%) and Millennium Management LLC (0.33%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna and Norbert G Riedel. View Institutional Ownership Trends for Aptinyx.
Which major investors are buying Aptinyx stock?
APTX stock was bought by a variety of institutional investors in the last quarter, including Frazier Management LLC, Partner Fund Management L.P., NF Trinity Capital Hong Kong Ltd, Victory Capital Management Inc., Laurion Capital Management LP, Millennium Management LLC, Citadel Advisors LLC and Partner Investment Management L.P.. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna and Norbert G Riedel. View Insider Buying and Selling for Aptinyx.
How do I buy shares of Aptinyx?
Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptinyx's stock price today?
One share of APTX stock can currently be purchased for approximately $22.81.
How big of a company is Aptinyx?
Aptinyx has a market capitalization of $714.16 million. Aptinyx employs 64 workers across the globe.
How can I contact Aptinyx?
Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]
MarketBeat Community Rating for Aptinyx (NASDAQ APTX)
MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
